← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	817	+15	+2%	$32.9B
2	2 Danaher DHR $158B	807	+28	+4%	$37.8B
3	3 Novartis NVS $279B	761	-2	-0.3%	$18.4B
4	4 Agilent Technologies A $49.1B	547	+29	+6%	$14.1B
5	5 Regeneron Pharmaceuticals REGN $80.1B	414	+43	+12%	$24B
6	6 Illumina ILMN $41B	348	+15	+5%	$11.4B
7	7 Revvity RVTY $17B	294	+10	+4%	$3.81B
8	8 Myriad Genetics MYGN $397M	267	+6	+2%	$2.45B
9	9 Charles River Laboratories CRL $14.4B	230	+5	+2%	$2.17B
10	10 Ionis Pharmaceuticals IONS $7.1B	204	+31	+18%	$3.91B
11	11 Bruker BRKR $8.47B	171	+6	+4%	$2.33B
12	12 Alnylam Pharmaceuticals ALNY $30B	164	+25	+18%	$3.28B
13	13 Sarepta Therapeutics SRPT $1.78B	134	+6	+5%	$1.29B
14	14 Azenta AZTA $1.63B	130	-1	-0.8%	$568M
15	15 DELISTED SANGAMO THERAPEUTICS INC SGMO	111	+12	+12%	$408M
16	16 Standard BioTools LAB $248M	89	+9	+11%	$510M
17	17 Fortress Biotech FBIO $63.4M	81	+13	+19%	$158M
18	18 Pacific Biosciences PACB $619M	81	+10	+14%	$184M
19	19 Precigen PGEN $2.64B	70	+70	–	$1.82B
20	20 DELISTED bluebird bio BLUE	67	+61	+1,017%	$236M
21	21 PTC Therapeutics PTCT $4.98B	61	+58	+1,933%	$297M
22	22 Lineage Cell Therapeutics LCTX $232M	56	-2	-3%	$63.9M
23	23 Invesco Biotechnology & Genome ETF PBE $421M	51	+11	+28%	$60.7M
24	24 Vericel Corp VCEL $2.06B	35	+1	+3%	$2.98M
25	25 Arrowhead Research ARWR $8.25B	34	+16	+89%	$69.4M